Cervical cancer stages IB1, IB2, and IIA1, including squamous cell carcinoma of the cervix, adenocarcinoma of the cervix, or adenosquamous carcinoma of the cervix.
Conditions
Interventions
Experimental group:total Müllerian duct compartment resection
Control group:Traditional Radical Hysterectomy
Sponsors
The second hospital of Dalian Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patient voluntarily participates in this study and signs the informed consent form; 2. Aged 18 to 75 years old; 3. Based on auxiliary examinations, preoperative diagnosis is cervical cancer stages IB1, IB2, or IIA1 [FIGO 2018]; 4. Pathologically confirmed as cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; 5. Preoperative imaging (MRI, CT, PET-CT) shows no definite parametrial invasion (i.e., not stage IIB) and no evidence of lymph node metastasis; 6. No prior history of radiotherapy or chemotherapy; 7. ECOG score 0–1; 8. Expected survival over 6 months; 9. Women of childbearing age must have a negative pregnancy test (serum or urine) within 7 days before enrollment and agree to use appropriate contraception during the study; 10. According to the investigator, there are no absolute surgical contraindications, the patient can tolerate surgery, and can comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1.Preoperative imaging (MRI, CT, PET-CT) indicates suspected lymph node metastasis, parametrial invasion, or distant metastasis; 2.Pathology confirms specific histological types, such as neuroendocrine tumors, serous carcinoma, gastric-type adenocarcinoma, clear cell carcinoma, or endometrioid adenocarcinoma; 3.Previous radiotherapy for pelvic malignancies; 4.History of partial hysterectomy or radical hysterectomy; 5.Active or uncontrolled severe infection; 6.Liver cirrhosis or decompensated liver disease; 7.Chronic renal insufficiency or renal failure; 8.Myocardial infarction, severe arrhythmia, and congestive heart failure = Grade 2 (New York Heart Association [NYHA] classification); 9.Patients with concurrent other malignancies requiring treatment and/or newly diagnosed malignancies within the past 5 years; 10.History of immunodeficiency, including HIV-positive status or other acquired or congenital immunodeficiency disorders; 11.Patients who have undergone pelvic artery embolization; 12.Patients with concomitant conditions requiring treatment with drugs that significantly impair hepatic or renal function, such as tuberculosis; 13.Patients unable to understand the study content, unable to cooperate, or refusing to sign the informed consent form; 14.Patients with concomitant diseases or other special circumstances that pose a serious threat to patient safety or interfere with study completion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year progression-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-year overall survival rate;Incidence of Perioperative Complications; | — |
Countries
China
Contacts
Public ContactJun Wang
The second hospital of Dalian Medical University
Outcome results
None listed